COL18A1 and non-small cell lung carcinoma: Recent preclinical study verified the synergy of rh‐endostatin and anti‐PD‐1 antibody in lung cancer mouse model,28 which laid a solid foundation for combination therapies of rh‐endostatin plus ICIs in the treatment of advanced‐stage NSCLC.